Clinical trials
Hemangioma, Capillary trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Unknown status | 6 |
| Terminated | 6 |
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| West China Hospital | 6 |
| Pierre Fabre Dermatology | 2 |
| The Hospital for Sick Children | 2 |
| University Hospital, Montpellier | 2 |
| University of California, Irvine | 2 |
| AFT Pharmaceuticals, Ltd. | 1 |
| Ain Shams University | 1 |
| Alice K. Gong | 1 |
| Assiut University | 1 |
| Auson Pharmaceuticals Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemangioma, Capillary | 47 |
| Hemangioma | 13 |
| Vascular Malformations | 4 |
| Hemangioma, Cavernous | 2 |
| Port-Wine Stain | 2 |
| Adenoviridae Infections | 1 |
| Anxiety Disorders | 1 |
| Arrhythmias, Cardiac | 1 |
| Arteriovenous Malformations | 1 |
| Astrocytoma | 1 |
Trials
Showing 26 to 47 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.